Christopher Heery
CIK 1789632 · CHIEF MEDICAL OFFICER · last filed 2026-04-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ACLX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
DURHAM, NC 27701
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Arcellx, Inc. (ACLX) Delisted | CHIEF MEDICAL OFFICER | 0 | $115.07 | $0 | -$29.60M | 46 | 2026-04-28 |
| DTIL | Chief Medical Officer | 83 | $6.78 | $563 | $30.0K | 2 | 2020-06-10 |
Recent Filings · Page 2 of 7
67 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-09-29 | Arcellx, Inc. (ACLX) Delisted | Sell (S) | −73 | -$5.9K | EDGAR |
| 2025-09-26 | Arcellx, Inc. (ACLX) Delisted | Sell (S) | −12,396 | -$993.2K | EDGAR |
| 2025-09-19 | Arcellx, Inc. (ACLX) Delisted | Sell (S) | −3,643 | -$291.5K | EDGAR |
| 2025-09-18 | Arcellx, Inc. (ACLX) Delisted | Notice (144) | −37,486 | -$2.86M | EDGAR |
| 2025-02-24 | Arcellx, Inc. (ACLX) Delisted | Notice (144) | −10,155 | -$647.8K | EDGAR |
| 2025-02-24 | Arcellx, Inc. (ACLX) Delisted | Mixed | +12,401 | -$647.8K | EDGAR |
| 2025-02-11 | Arcellx, Inc. (ACLX) Delisted | Exer (M) | +22,556 | $0 | EDGAR |
| 2025-01-10 | Arcellx, Inc. (ACLX) Delisted | Mixed | +8,736 | -$581.3K | EDGAR |
| 2025-01-10 | Arcellx, Inc. (ACLX) Delisted | Mixed | +7,071 | -$466.2K | EDGAR |
| 2025-01-07 | Arcellx, Inc. (ACLX) Delisted | Notice (144) | −8,100 | -$611.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.